177-lu labeled active site inhibited factor vii
AssigneeMinerva Imaging APS
InventorsAndreas KJAER, Carsten HAAGEN NIELSEN
Life of this patent
Estimating the term…
Abstract
There is provided a 177-Lu labelled peptide for site-specific targeting of TF thereby enabling treatment of a cancer disease associated with high TF expression; e.g. treatment of cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
Claims13
A therapeutic agent for targeted radionuclide therapy of Tissue Factor expressing cancers, the therapeutic agent comprising a 177-Lu labelled Tissue Factor binding peptide conjugate, wherein the peptide is an active site inhibited factor Vlia (FVIIai), and is coupled to 177-Lu by a chelating agent selected from the group consisting of DTPA, DOTA, NOTA, NODAGA, CB-TE2A, H4octapa, or p-SCN-Bn-H4octapa.
A method of treatment of a cancer disease associated with high TF expression, the method comprising administering to a patient a 177-Lu labelled Tissue Factor binding peptide conjugate, wherein the peptide is an active site inhibited factor Vlia (FVIIai), and is coupled to 177-Lu by a chelating agent selected from the group consisting of DTPA, DOTA, NOTA, NODAGA, CB-TE2A, H4octapa, or p-SCN-Bn-H4octapa.
17. (canceled)
Dependencies are inferred from the claim text.